Animal Model Core

核心A：动物模型核心 动物模型核心A的目的是为PPG的每位研究者提供广泛的动物模型， 评估脂质代谢、血栓形成和相关血管疾病的模型。 项目1）丹尼尔A.劳伦斯博士，内科心血管内科教授 医学：派-1在脂质代谢中的新作用的表征。核心A将提供外科手术 支持劳伦斯博士的体内实验，如本资助申请所述。核心A也将是 负责体外实验中小鼠巨噬细胞和脂肪细胞的细胞分离 在项目1中，为Lawrence博士评估派-1在脂质代谢中的作用的实验。 项目2）托马斯W.韦克菲尔德，医学博士，外科血管外科主任： 派-1在静脉血栓形成中的作用核心A将提供三种静脉血栓形成的动物模型 用于项目2的体外试验。这些动物模型包括：1）下腔静脉（IVC） 静脉血栓形成的狭窄模型和2）静脉血栓形成的IVC结扎模型。核心A将 执行韦克菲尔德博士和Peter K博士概述的实验的所有外科手术。Henke在Project 2. 项目3）大卫J.平斯基，医学博士，内科心血管内科主任： 冠状动脉移植血管病的血栓/纤溶平衡。动物模型核心A将 为平斯基博士在本资助申请中概述的小鼠体内实验提供手术支持。核心 A将有助于在拟议的移植相关的小鼠超声心动图图像的采集 冠状动脉疾病（TCAD）实验。动物模型核心A将负责 对同种异体移植物受体的术前抗体施用和小鼠同种异体移植物的每日评估 以确定存活率。 项目4）医学博士大卫金斯伯格，内科学系医学遗传学部 人类遗传学系：确定血栓形成修饰基因和新型抗凝剂， 斑马鱼。核心A将直接与Ginsburg博士（项目4）合作，并协调具体的核心A 化学基因组学中心（CCG）的大卫谢尔曼博士与Co-Pi的相互作用， 通过化学筛选来鉴定斑马鱼（Danio rerio）中的新型抗凝剂这些筛选将 专注于脂质紊乱和血管疾病，目标是提供新的药物疗法来治疗人类 止血障碍。 核心A计划将成为PPG项目的核心部分，并将使所有参与的研究者受益。

Core A: Animal Model Core The purpose of the Animal Model Core A is to provide each investigator of the PPG a wide array of animal models to assess lipid metabolism, thrombosis, and related vascular disorders. Project 1) Daniel A. Lawrence, Ph.D., Professor of Cardiovascular Medicine, Department of Internal Medicine: Characterization of a Novel Role for PAI-1 in Lipid Metabolism. Core A will provide surgical support of Dr. Lawrence's in vivo experiments as outlined in this grant application. Core A will also be responsible for the cellular isolation of murine macrophages and adipocytes for in vitro experiments outlined in Project 1 for experiments evaluating the role of PAI-1 in lipid metabolism for Dr. Lawrence. Project 2) Thomas W. Wakefield, M.D., Head, Vascular Surgery Section, Department of Surgery: Role of PAI-1 in Venous Thrombogenesis. Core A will provide three animal models of venous thrombosis for in vitro testing for Project 2. These animal models include the following: 1) Inferior Vena Cava (IVC) Stenosis Model of Venous Thrombosis and 2) IVC ligation Model of Venous Thrombosis. Core A will perform all surgical procedures for experiments outlined by Dr. Wakefield and Dr. Peter K. Henke in Project 2. Project 3) David J. Pinsky, M.D., Chief, Cardiovascular Medicine, Department of Internal Medicine: Thrombotic/fibrinolytic Balance in Coronary Transplant Vasculopathy. Animal Model Core A will provide surgical support of Dr. Pinsky's murine in vivo experiments as outlined in this grant application. Core A will facilitate the acquisition of mouse echocardiograph images in the proposed transplant associated coronary artery disease (TCAD) experiments. Animal Model Core A will be responsible for both the preoperative administration of antibodies to allograft recipients and the daily assessment of mouse allograft to determine survival rates. Project 4) David Ginsburg, M.D., Division of Medical Genetics, Department of Internal Medicine and Department of Human Genetics: Identifying Thrombosis Modifier Genes and Novel Anticoagulants in Zebra fish. Core A will directly collaborate with Dr. Ginsburg (Project 4) and coordinate specific Core A interactions with Co-Pi Dr. David Sherman of the Center for Chemical Genomics (CCG) to develop high throughput chemical screens to identify novel anticoagulants in zebrafish (Danio rerio) These screens will focus on lipid disorders and vascular disease with the goal of providing novel drug therapies to treat human disorders of hemostasis. It is intended that Core A will be a central part of the PPG Program and will benefit all investigators involved.